The short version of NR1D1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
=== Circulatory and gas exchange system === The body cavity contains the circulatory or haemal system. The vessels form three rings: one around the mouth (the hyponeural haemal ring), another around the digestive system (the gastric ring), and the third near the aboral surface (the genital ring). The heart beats about six times a minute and is at the apex of a vertical channel (the axial vessel) that connects the three rings. Blood does not contain a pigment such as heme, but is probably used to transport nutrients around the body. Gas exchange mainly takes place through gills known as papulae, which are thin-walled bulges along the aboral surface of the arms. Oxygen is transferred from these to the coelomic fluid, which moves gas around the body.
His4 catalyzes the oxidation of l-histidinol to form l-histidinal, an amino aldehyde. In the last step, l-histidinal is converted to l-histidine. The histidine biosynthesis pathway has been studied in the fungus Neurospora crassa, and a gene (His-3) encoding a multienzyme complex was found that was similar to the His4 gene of the bacterium E. coli. A genetic study of N. crassa histidine mutants indicated that the individual activities of the multienzyme complex occur in discrete, contiguous sections of the His-3 genetic map, suggesting that the different activities of the multienzyme complex are encoded separately from each other. However, mutants were also found that lacked all three activities simultaneously, suggesting that some mutations cause loss of function of the complex as a whole. Like animals and microorganisms, plants need histidine for their growth and development. But unlike animals, microorganisms and plants can synthesize histidine. Both synthesize histidine from the biochemical intermediate phosphoribosyl pyrophosphate. In general, the histidine biosynthesis is very similar in plants and microorganisms.
It includes a variety of interventions, including support for improved food production, a strengthening of social protection, and integration of the right to food into national legislation. The EndingHunger campaign is an online communication campaign whose goal is to raise awareness about hunger. The campaign has created viral videos depicting celebrities voicing their anger about the large number of hungry people in the world. After the Millennium Development Goals expired in 2015, the Sustainable Development Goals became the main global policy focus to reduce hunger and poverty. In particular, Goal 2: Zero Hunger sets globally agreed-upon targets to wipe out hunger, end all forms of malnutrition, and make agriculture sustainable. The partnership Compact2025 develops and disseminates evidence-based advice to politicians and other decision-makers, with the goal of ending hunger and undernutrition by 2025. The International Food Policy Research Institute (IFPRI) led the partnership, with the involvement of UN organisations, non-governmental organizations (NGOs), and private foundations.
=== EC 1.17.98 With other, known, physiological acceptors === EC 1.17.98.1: bile-acid 7α-dehydroxylase. Now known to be catalyzed by multiple enzymes. EC 1.17.98.2: bacteriochlorophyllide c C-71-hydroxylase EC 1.17.98.3: formate dehydrogenase (coenzyme F420) EC 1.17.98.4: formate dehydrogenase (hydrogenase)
Sources: en.wikipedia.org
== Medical application == S. helianthus shows a variety of promising applications in the medical field due to its toxin-producing capability. ShK-186, a peptide inhibitor, is a toxin that has been previously implemented in clinical trials for its potential treatment of autoimmune diseases. It has been further developed into an “investigational drug”, known as Dalazatide, in which it targets the disease-causing cells corresponding to ailments including type 1 diabetes, lupus erythematosus and multiple sclerosis. The aforementioned cytolysins, St I and St II, have also shown pharmacological potential in studies with guinea pig models, with direct implications on neural and cardiac activity. Due to its capability of protease inhibition, ShPI-1 is another toxin with medical potential. This toxin is a “non-specific inhibitor” and provides a variant with “increased biomedical potential” for its inhibition properties. Though many of these toxins require further research, S. helianthus serves great potential in biomedical applications for toxin production.
lagging strand In DNA replication, the nascent strand for which DNA polymerase's direction of synthesis is away from the replication fork, which necessitates a complex and discontinuous process in contrast to the streamlined, continuous synthesis of the other nascent strand, known as the leading strand, which occurs simultaneously. Because DNA polymerase works only in the 5' to 3' direction, but the lagging strand's overall direction of chain elongation must ultimately be the opposite (i.e. 3' to 5', toward the replication fork), elongation must occur by an indirect mechanism in which a primase enzyme synthesizes short RNA primers complementary to the template DNA, and DNA polymerase then extends the primed segments into short chains of nucleotides known as Okazaki fragments. The RNA primers are then removed and replaced with DNA, and the Okazaki fragments are joined by DNA ligase.
On 10 January 1973, negotiations broke down when Kissinger demanded the release of all American POWs in North Vietnam once a peace agreement was signed, but offered no guarantees about Viet Cong prisoners being held in South Vietnam. Tho stated: "I cannot accept your proposal. I completely reject it". Tho wanted the release of all prisoners once a peace agreement was signed, which led Kissinger to say this was an unreasonable demand. Tho, who had been tortured as a young man by the French colonial police for advocating Vietnamese independence, shouted: "You have never been a prisoner. You don't understand suffering. It's unfair". Kissinger finally offered the concession that the United States would use "maximum influence" to pressure the South Vietnamese government to release all Viet Cong prisoners within sixty days of a peace agreement being signed. Thiệu once again rejected the peace agreement, only to receive an ultimatum from Nixon: "You must decide now whether you desire to continue our alliance or whether you want me to seek a settlement with the enemy which serves U.S. interests alone". Nixon told Kissinger: "Brutality is nothing. You have never seen it if this son-of-a-bitch doesn't go along, believe me". Nixon's threat served its purpose, and Thiệu reluctantly accepted the peace agreement. On 23 January 1973, at 12:45 pm, Kissinger and Tho signed a peace agreement in Paris that called for the complete withdrawal of all U.S. forces from Vietnam by March in exchange for North Vietnam freeing all the U.S. POWs.
Fe(II) + H2O2 → Fe(III)OH + HO· The Fenton reaction explains the toxicity of hydrogen peroxides because the hydroxyl radicals rapidly and irreversibly oxidize all organic compounds, including proteins, membrane lipids, and DNA. Hydrogen peroxide is a significant source of oxidative DNA damage in living cells. DNA damage includes formation of 8-Oxo-2'-deoxyguanosine among many other altered bases, as well as strand breaks, inter-strand crosslinks, and deoxyribose damage. By interacting with Cl−, hydrogen peroxide also leads to chlorinated DNA bases. Hydroxyl radicals readily damage vital cellular components, especially those of the mitochondria. The compound is a major factor implicated in the free-radical theory of aging, based on its ready conversion into a hydroxyl radical.
Atmospheric pressure is variable but 101.325 and 100 kilopascals (1013.25 and 1000.00 mbar) are common standard or reference pressures. Deep space is generally much more empty than any artificial vacuum. It may or may not meet the definition of high vacuum above, depending on what region of space and astronomical bodies are being considered. For example, the MFP of interplanetary space is smaller than the size of the Solar System, but larger than small planets and moons. As a result, solar winds exhibit continuum flow on the scale of the Solar System, but must be considered a bombardment of particles with respect to the Earth and Moon. Perfect vacuum is an ideal state of no particles at all. It cannot be achieved in a laboratory, although there may be small volumes which, for a brief moment, happen to have no particles of matter in them. Even if all particles of matter were removed, there would still be photons, as well as dark energy, virtual particles, and other aspects of the quantum vacuum.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.